Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Exclusion Criteria

• •1. Type 1 diabetes
• •2. Treatment with GLP-1 receptor agonists or DPP-4 inhibitors within the last 4 weeks
• •3. Patients with familiar or personal history of multiple endocrine neoplasia-type 2 or medullary C-cell cancer
• •4. Renal impairment (eGFR \< 30 mL/min)
• •5. Occurrence of acute vascular events within 6 weeks before screening and randomization
• •6. Known or suspected hypersensitivity to Liraglutide
• •7. Pregnant females as determined by positive (serum or urine) hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol.
• •8. Lactating females
• •9. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.
• •10. The subject received an investigational drug within 30 days prior to inclusion into this study.
• •11. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study.
• •12. The subject is unwilling or unable to follow the procedures outlined in the protocol.
• •13. The subject is mentally or legally incapacitated.